Analyst consensus rating
Jazz Pharmaceuticals Analyst Rating: Buy
JAZZ is rated Buy by 20 analysts with a $281.35 target. As of 2026-08-26.
Direct answer
Jazz Pharmaceuticals's consensus rating is Buy.
20 analysts are included in the current consensus when a coverage count is available.
The same consensus reports an average price target of $281.35.
Forecast evidence checked August 26, 2026.
Get free Jazz Pharmaceuticals email updates.
Bullstory sends one daily email when new analysis or important company news is available.
Verified data
- Current price
- $260.23
- Average price target
- $281.35
- High price target
- $315.00
- Low price target
- $196.00
- Low target gap
- -24.7%
- Target upside
- +8.1%
- High target gap
- +21%
- Target range width
- 45.7%
- Consensus rating
- Buy
- Analysts
- 20
- Evidence date
- August 26, 2026
- Valid through
- September 2, 2026
Explore related company data
Read the frequently asked questions.
What is the analyst consensus rating for Jazz Pharmaceuticals?
Jazz Pharmaceuticals has a verified Buy consensus. The same dataset has an average price target of $281.35.
How far are Jazz Pharmaceuticals's low and high targets from the recorded price?
The low target implies -24.7%, while the high target implies +21%.
How many analysts are included in Jazz Pharmaceuticals's consensus?
The verified consensus includes 20 analysts.
How is Jazz Pharmaceuticals's target upside or downside calculated?
The average target of $281.35 is divided by the recorded price of $260.23, then one is subtracted to produce +8.1%. This does not guarantee a future return.
When was Jazz Pharmaceuticals's analyst forecast verified?
The data was verified on 2026-08-26. The dataset is valid through 2026-09-02.